Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2005.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Minimally invasive management of cervical spondylodiscitis. A multicenter experience.
Neurosurg Rev
January 2025
Neurosurgery department Strasbourg University Hospital, Hautepierre University Hospital, 2 Avenue de Molière, Strasbourg, France.
The urgent etiological diagnosis represents the main management objective of cervical spondylodiscitis (CSD) to start as soon as possible antibiotic treatment to prevent neurological deterioration. The present study aimed to evaluate a multicenter experience implementing a minimally invasive surgical approach (MISA) to manage CSD such pathology vs the most complex and aggressive surgical strategies currently used.This retrospective multicenter study used a database of 70 patients from five European neurosurgical centers.
View Article and Find Full Text PDFThe Evolution of Treatment-Free Remission.
Blood
January 2025
South Australian Health & Medical Research Institute, Australia.
One of the most remarkable achievements of the TKI era has been the capacity to induce deep molecular remissions that are sustainable off therapy in chronic myeloid leukemia (CML) patients - treatment-free remission (TFR). TFR was first described in a handful of patients within 3-4 years of imatinib approval. In 2004 TFR was tested in a small French pilot study, followed soon after by the French STIM and Australasian TWISTER studies.
View Article and Find Full Text PDFRecognition memory decline is associated with the progression to prodromal Alzheimer's disease in asymptomatic at-risk individuals.
J Neurol
December 2024
Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France.
Episodic memory (EM) alterations are a hallmark of Alzheimer's disease (AD). We assessed EM longitudinally in cognitively normal elders at-risk for AD (with subjective memory complaints), as a function of amyloid-β (Aβ) burden, neurodegeneration (N), and progression to prodromal AD. We stratified 264 INSIGHT-preAD study subjects in controls (Aβ-/N-), stable/N- or N + (Aβ +), and progressors/N- or N + (Aβ +) groups (progressors were included only until AD-diagnosis).
View Article and Find Full Text PDF[The historical synchronicities of the Eli Lilly Canada Chair on schizophrenia research].
Sante Ment Que
December 2024
Université de Montréal, Québec, Canada.
Background Created in 2004, the Eli Lilly Canada Chair on schizophrenia research was funded by Eli Lilly, the Institut universitaire en santé mentale de Montréal, Hôpital Sacré-Coeur and Centre hospitalier de l'Université de Montréal. The aim of this article is to provide an historical overview of the scientific activities of the Chair since its inception. Method In order to carry out this historical account, we adopted a bibliometric approach.
View Article and Find Full Text PDFReal-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Lung Cancer
November 2024
CHI Créteil, Créteil, France.
Background: BRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in phase II. This study (IFCT-2004 BLaDE study) reported the efficacy of D-T combination in a large retrospective French real-world multicenter cohort of patients with advanced BRAF V600E-mutated NSCLC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!